LHLaura J. Henze

Laura J. Henze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura J. Henze has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Establishing Experimental Parameters for Biphasic Transfer in Vitro Lipolysis Model

    by Hannah Sofie Kirschbaum, Christian Jede, Laura J. Koehl, Martin Kuentz, René Holm, Brendan T. Griffin, Johannes Andreas Blechar, Patrick J. Odwyer

    Lipid-based‑formulations (LBFs) are widely used to improve oral bioavailability of poorly water‑soluble drugs. Despite their widespread use in predicting formulation performance, standard in vitro lipolysis assays often lack an absorptive sink and fail to capture the transition from gastric to intestinal environments, thereby reducing their predictive relevance for in vivo outcomes. The aim of this study was to develop a biphasic in vitro lipolysis model incorporating an absorptive sink. In this model, the absorptive sink was provided by a decanol layer, and to simulate gastrointestinal transit, two dynamic pH‑transition approaches were employed: a biphasic GI‑transfer model and a biphasic pH‑shift model. Using nilotinib‑loaded LBFs, the study established conditions for this biphasic system and examined how media composition and lipase source influence drug concentrations during formulation dispersion, digestion, and partitioning into the organic sink. The results showed that digestion experiments conducted with either porcine pancreatin or Palatase® 20000 L increased the concentration of nilotinib in the aqueous digestion medium, which correspondingly reduced partitioning of the drug into the decanol layer. For the readily dispersible Type III LBF in the biphasic GI‑transfer setup, nilotinib permeation into the decanol layer decreased compared with a lipid‑free control, likely due to improved drug solubilization in the aqueous digestion phase. In contrast, the poorly dispersible Type I LBF was better suited to the biphasic pH‑shift setup, but it showed higher drug levels in the decanol layer, reflecting rapid partitioning of lipids—and associated crystalline drug—into the organic phase. Overall, this study establishes suitable conditions for evaluating the lipolysis of LBFs during a dynamic pH transition in the presence of an absorptive sink. This advanced approach provides additional insight to explore digestion‑mediated and/or pH‑mediated supersaturation during digestion of LBFs.

  • Open Access

    pH-stat versus pH-shift lipolysis model: Exploring in vitro-in vivo relationships for lipid-based formulations of nilotinib

    by Hannah S. Kirschbaum, Niklas J. Koehl, Johannes A. Blechar, Christina Wiesinger, Laura J. Koehl, Patrick J. O´dWyer, Martin Kuentz, René Holm, Christian Jede, Brendan T. Griffin


  • Open Access

    Toward the establishment of a standardized pre-clinical porcine model to predict food effects – Case studies on fenofibrate and paracetamol

    by Laura J. Henze, Niklas J. Koehl, Joseph P. O'SHea, René Holm, Maria Vertzoni, Brendan T. Griffin


  • The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review

    by Laura J. Henze, Niklas J. Koehl, Joseph P. O'Shea, Edmund S. Kostewicz, René Holm, Brendan T. Griffin

    Objectives In pharmaceutical drug development, preclinical tests in animal models are essential to demonstrate whether the new drug is orally bioavailable and to gain a first insight into in vivo pharmacokinetic parameters that can subsequently be used to predict human values. Despite significant advances in the development of bio‐predictive in vitro models and increasing ethical expectations for reducing the number of animals used for research purposes, there is still a need for appropriately selected pre‐clinical in vivo testing to provide guidance on the decision to progress to testing in humans. The selection of the appropriate animal models is essential both to maximise the learning that can be obtained from such experiments and to avoid unnecessary testing in a range of species. Key findings The present review, provides an insight into the suitability of the pig model for predicting oral bioavailability in humans, by comparing the conditions in the GIT. It also contains a comparison between the bioavailability of compounds dosed to both humans and pigs, to provide an insight into the relative correlation and examples on why a lack of correlation may be observed. Summary While there is a general trend towards predicting human bioavailability from pig data, there is considerable variability in the data set, most likely reflecting species specific differences in individual drug metabolism. Nonetheless, the correlation between pigs vs. humans was comparable to that reported for dogs vs. humans. The presented data demonstrate the suitability of the pig as a preclinical model to predict bioavailability in human.